Aliases & Classifications for Breast Disease

MalaCards integrated aliases for Breast Disease:

Name: Breast Disease 12 15 17
Breast Diseases 54 42 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:3463
MeSH 43 D001941
NCIt 49 C26709
SNOMED-CT 67 79604008
UMLS 71 C0006145

Summaries for Breast Disease

MedlinePlus : 42 Most women experience breast changes at some time. Your age, hormone levels, and medicines you take may cause lumps, bumps, and discharges (fluids that are not breast milk). If you have a breast lump, pain, discharge or skin irritation, see your health care provider. Minor and serious breast problems have similar symptoms. Although many women fear cancer, most breast problems are not cancer. Some common breast changes are Fibrocystic breast changes - lumpiness, thickening and swelling, often just before a woman's period Cysts - fluid-filled lumps Fibroadenomas - solid, round, rubbery lumps that move easily when pushed, occurring most in younger women Intraductal papillomas - growths similar to warts near the nipple Blocked milk ducts Milk production when a woman is not breastfeeding NIH: National Cancer Institute

MalaCards based summary : Breast Disease, also known as breast diseases, is related to microglandular adenosis and hypertrophy of breast, and has symptoms including pruritus, exanthema and pelvic pain. An important gene associated with Breast Disease is PRLR (Prolactin Receptor), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Hydrocortisone and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and thyroid, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Disease Ontology : 12 A thoracic disease that is located in the breast.

Wikipedia : 74 Breast diseases make up a number of conditions. The most common symptoms are a breast mass, breast pain,... more...

Related Diseases for Breast Disease

Diseases related to Breast Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 411, show less)
# Related Disease Score Top Affiliating Genes
1 microglandular adenosis 34.0 TP53 PGR ESR1 ERBB2
2 hypertrophy of breast 33.1 TP53 PGR ESR1 ERBB2 BRCA1
3 breast fibroadenoma 32.1 TP53 TFF1 PGR ESR1 ERBB2 CTSD
4 breast cancer 32.0 VEGFA TP53 TFF1 RHOC PRLR PGR
5 in situ carcinoma 31.9 TP53 PGR KRT5 ESR1 ERBB2 EGF
6 papilloma 31.8 VEGFA TP53 KRT5 ESR1 CASP3
7 ductal carcinoma in situ 31.8 VEGFA TP53 PGR KRT5 ESR2 ESR1
8 gynecomastia 31.7 PGR ESR2 ESR1 ERBB2
9 intraductal papilloma 31.4 PGR KRT5 ESR1 ERBB2
10 lobular neoplasia 31.4 TP53 PRLR PGR KRT5 ESR2 ESR1
11 breast ductal carcinoma 31.2 VEGFA TP53 TFF1 PGR KRT5 ESR2
12 mammary paget's disease 31.1 PGR ESR1 ERBB2
13 mammographic density 31.1 PGR IGFBP3 IGF1 ESR1 CYP1B1 CYP1A1
14 insulin-like growth factor i 31.0 IGFBP3 IGF1 ESR1 EGF
15 female breast cancer 31.0 TP53 PGR IGF1 ESR1 ERBB2 CYP1A1
16 endometriosis 31.0 VEGFA PGR MIR199A1 ESR2 ESR1 CYP1B1
17 leiomyoma 30.8 PGR ESR2 ESR1 EGF COMT
18 galactorrhea 30.8 PRLR IGF1
19 estrogen excess 30.8 PGR ESR2 ESR1
20 sporadic breast cancer 30.8 TP53 PGR ESR2 ESR1 ERBB2 BRCA1
21 tubular adenocarcinoma 30.7 PGR ESR1 ERBB2
22 bilateral breast cancer 30.7 PGR ESR1 ERBB2 BRCA1
23 pregnancy adenoma 30.6 PGR KRT5
24 cystitis 30.6 VEGFA TP53 IGF1 EGF
25 breast malignant phyllodes tumor 30.6 TP53 PGR KRT5 ESR1 ERBB2
26 meningioma, familial 30.6 VEGFA TP53 PGR IGF1 ESR1 ERBB2
27 apocrine adenocarcinoma 30.6 PGR KRT5 ESR1 ERBB2
28 inflammatory breast carcinoma 30.6 RHOC PGR ESR1 ERBB2
29 cervical cancer 30.6 VEGFA TP53 IGFBP3 ESR1 ERBB2 EGF
30 vascular disease 30.6 VEGFA TP53 MIR199A1 IGF1 CASP3
31 vulvar disease 30.6 TP53 PGR ERBB2
32 li-fraumeni syndrome 30.6 TP53 ESR1 ERBB2 BRCA1
33 skin melanoma 30.6 TP53 MIR199A1 ERBB2 CASP3
34 body mass index quantitative trait locus 11 30.5 VEGFA TP53 MIR199A1 IGFBP3 IGF1 ESR1
35 fallopian tube carcinoma 30.5 VEGFA TP53 PGR ESR1 ERBB2 BRCA1
36 breast carcinoma in situ 30.5 VEGFA TP53 PGR KRT5 ESR1 ERBB2
37 prostatic hypertrophy 30.5 PGR ESR1 EGF
38 ovarian disease 30.5 VEGFA TP53 PGR MIR199A1 IGF1 ESR2
39 gastric cancer 30.4 VEGFA TP53 TFF1 PGR MIR199A1 IGF1
40 rare non-malformative breast disease 12.1
41 mastitis 11.8
42 diabetic mastopathy 11.4
43 infant gynecomastia 11.3
44 breast abscess 11.3
45 multiple fibroadenomas of the breast 11.1
46 gastric adenocarcinoma 11.0 VEGFA TP53 TFF1 IGF1 ESR1 ERBB2
47 mixed cell adenoma 10.9 IGF1 EGF CTSD
48 endometrial clear cell adenocarcinoma 10.9 TP53 ESR1 CTSD
49 colon adenocarcinoma 10.9 VEGFA TP53 ESR2 ESR1 ERBB2 EGF
50 cervical adenocarcinoma 10.9 TP53 ESR1 ERBB2 EGF CASP3
51 ewing sarcoma 10.9 VEGFA TP53 IGFBP3 IGF1 ERBB2 CASP3
52 hair disease 10.9 VEGFA TP53 IGF1 ERBB2
53 pancreatic ductal carcinoma 10.9 VEGFA TP53 ERBB2 EGF
54 colorectal adenocarcinoma 10.9 VEGFA TP53 ERBB2 EGF CASP3
55 esophageal adenosquamous carcinoma 10.9 KRT5 IGFBP3 ERBB2
56 colorectal adenoma 10.9 VEGFA TP53 IGFBP3 IGF1
57 tongue squamous cell carcinoma 10.9 VEGFA TP53 RHOC EGF CASP3
58 sweat gland neoplasm 10.9 TP53 KRT5 ERBB2
59 squamous cell carcinoma 10.9 VEGFA TP53 ERBB2 EGF CYP1A1 CASP3
60 traumatic brain injury 10.9 IGF1 COMT CASP3
61 brain injury 10.9 IGF1 COMT CASP3
62 intrahepatic cholestasis of pregnancy 10.9 TP53 ESR2 ESR1 CYP1A1
63 exudative vitreoretinopathy 1 10.9 VEGFA IGFBP3 IGF1 CASP3
64 endometrial adenocarcinoma 10.9 VEGFA TP53 PGR IGF1 ESR2 ESR1
65 donohue syndrome 10.9 IGFBP3 IGF1 EGF
66 fat necrosis of breast 10.9
67 breast angiomatosis 10.9
68 uterine benign neoplasm 10.9 VEGFA TP53 PGR IGF1 ESR2 ESR1
69 reproductive organ benign neoplasm 10.9 VEGFA TP53 PGR IGF1 ESR2 ESR1
70 hydrocephalus 10.9 VEGFA TP53 IGFBP3 IGF1 CASP3
71 amelogenesis imperfecta, type ig 10.9 TFF1 PGR IGF1 ESR2 ESR1 ERBB2
72 lipid-rich carcinoma 10.9 PRLR PGR KRT5 ESR1 ERBB2
73 amelogenesis imperfecta 10.9 PGR ESR2 ESR1 ERBB2
74 asperger syndrome 10.9 IGF1 CYP1B1 CYP1A1 COMT
75 slipped capital femoral epiphysis 10.9 IGFBP3 IGF1
76 gastrointestinal stromal tumor 10.9 VEGFA TP53 IGFBP3 ERBB2 CASP3
77 comedo carcinoma 10.9 TP53 PGR ESR1 ERBB2
78 breast adenocarcinoma 10.9 TP53 PGR ESR1 ERBB2 EGF CYP1A1
79 suppression of tumorigenicity 12 10.9 VEGFA TP53 KRT5 IGFBP3 IGF1 ESR1
80 pheochromocytoma 10.9 VEGFA IGF1 ERBB2 EGF COMT CASP3
81 intraductal breast neoplasm 10.9 TP53 PGR KRT5 ESR1 ERBB2
82 gliosarcoma 10.9 VEGFA TP53 ERBB2 EGF
83 sebaceous adenocarcinoma 10.9 TP53 KRT5 ERBB2
84 sweat gland cancer 10.9 TP53 PGR KRT5 ESR1 ERBB2
85 mixed cell type cancer 10.9 TP53 PGR KRT5 ESR1 ERBB2
86 breast sarcoma 10.9 TP53 PGR ESR1 ERBB2
87 teeth hard tissue disease 10.9 PGR IGF1 ESR2 ESR1 ERBB2
88 uterine carcinosarcoma 10.9 VEGFA TP53 PGR ESR2 ESR1 ERBB2
89 lipid-rich breast carcinoma 10.9 PRLR PGR KRT5 ERBB2
90 carcinosarcoma 10.9 TP53 PGR ERBB2
91 pancreatic adenocarcinoma 10.9 VEGFA TP53 RHOC IGF1 ESR1 ERBB2
92 cerebral meningioma 10.9 PRLR PGR IGF1 EGF
93 adenomyosis 10.9 VEGFA TP53 PGR ESR2 ESR1
94 wilms tumor 1 10.9 VEGFA TP53 PGR IGF1 ESR1 ERBB2
95 leiomyoma, uterine 10.9 PGR IGF1 ESR2 ESR1 EGF COMT
96 breast papillary carcinoma 10.9 PGR KRT5 ESR1 ERBB2
97 mucinous adenocarcinoma 10.9 VEGFA TP53 PGR ESR1 ERBB2
98 myeloma, multiple 10.9 VEGFA TP53 MIR199A1 IGF1 ESR1 ERBB2
99 osteoporosis 10.9 VEGFA TP53 PGR IGFBP3 IGF1 ESR2
100 keratopathy 10.9 TP53 IGF1 CYP1B1
101 adenosarcoma 10.9 TP53 PGR ESR1 ERBB2
102 breast metaplastic carcinoma 10.9 PGR KRT5 ESR1 ERBB2
103 bartholin's gland adenoma 10.9 TP53 PGR ESR1
104 bartholin's gland benign neoplasm 10.9 TP53 PGR ESR1
105 oropharynx cancer 10.9 VEGFA TP53 PGR KRT5 ERBB2 EGF
106 autism spectrum disorder 10.9 IGFBP3 IGF1 ESR2 ESR1 COMT CASP3
107 vestibular gland benign neoplasm 10.9 TP53 PGR ESR1
108 glioblastoma multiforme 10.9 VEGFA TP53 RHOC IGF1 ESR1 ERBB2
109 progesterone-receptor positive breast cancer 10.9 PGR ESR2 ESR1 ERBB2
110 glassy cell carcinoma of the cervix 10.9 PGR ESR1 ERBB2
111 endometrial hyperplasia 10.9 VEGFA TP53 PGR ESR2 ESR1
112 secondary adrenal insufficiency 10.9 IGFBP3 IGF1
113 ovarian seromucinous carcinoma 10.9 TP53 PGR ESR1
114 pelvic organ prolapse 10.9 TP53 PGR ESR2 ESR1
115 eye disease 10.9 VEGFA TP53 MIR199A1 IGFBP3 IGF1 EGF
116 breast osteosarcoma 10.9 PGR KRT5 ESR1 ERBB2
117 cribriform carcinoma 10.9 PGR KRT5 ESR1 ERBB2
118 bizarre leiomyoma 10.9 TP53 PGR ESR1
119 apocrine adenosis of breast 10.9 TP53 PGR ERBB2
120 breast scirrhous carcinoma 10.9 PGR ESR1 ERBB2
121 oncocytic breast carcinoma 10.9 PGR ESR1 ERBB2
122 autonomic nervous system neoplasm 10.9 VEGFA TP53 MIR199A1 ERBB2 EGF CASP3
123 peripheral nervous system neoplasm 10.9 VEGFA TP53 MIR199A1 ERBB2 EGF CASP3
124 clear cell adenocarcinoma 10.9 TP53 PGR ESR1
125 peritoneum cancer 10.9 TP53 KRT5 ERBB2 BRCA1
126 sweat gland disease 10.9 PGR KRT5 ESR1 ERBB2
127 glioma susceptibility 1 10.9 VEGFA TP53 ERBB2 CASP3
128 adenosquamous carcinoma 10.9 TP53 PGR KRT5 CTSD
129 medulloblastoma 10.9 VEGFA TP53 IGFBP3 ESR2 ERBB2 EGF
130 nonmucinous bronchioloalveolar adenocarcinoma 10.9 ESR2 ESR1
131 malignant spiradenoma 10.9 TP53 KRT5
132 esophageal cancer 10.9 VEGFA TP53 MIR199A1 IGFBP3 IGF1 ERBB2
133 mucoepidermoid esophageal carcinoma 10.9 TP53 KRT5
134 malignant glioma 10.9 VEGFA TP53 EGF CASP3
135 cervical mucinous adenocarcinoma 10.9 TP53 PGR ESR1
136 progesterone resistance 10.9 PGR ESR2 ESR1
137 progesterone-receptor negative breast cancer 10.9 PGR ESR1 ERBB2
138 neuroblastoma 10.9 VEGFA TP53 IGF1 ESR1 ERBB2 EGF
139 tongue disease 10.9 VEGFA TP53 MIR199A1 EGF CASP3
140 mutagen sensitivity 10.9 TP53 IGF1 BRCA1
141 vaginal cancer 10.9 TP53 PGR ESR1
142 gastric papillary adenocarcinoma 10.9 TP53 ERBB2
143 salivary gland disease 10.9 TP53 KRT5 ERBB2
144 gastric diffuse adenocarcinoma 10.9 TP53 PGR ERBB2
145 oral cavity cancer 10.9 VEGFA TP53 MIR199A1 ERBB2 CYP1A1
146 gender identity disorder 10.9 PGR ESR2 ESR1
147 breast mucinous carcinoma 10.9 PGR KRT5 ERBB2
148 pleural cancer 10.9 VEGFA TP53 KRT5
149 breast neuroendocrine neoplasm 10.9 PGR ESR1 ERBB2
150 endocervical carcinoma 10.9 TP53 PGR ESR1
151 bile duct cancer 10.9 VEGFA TP53 MIR199A1 ERBB2 EGF
152 bile duct adenocarcinoma 10.9 VEGFA TP53 MIR199A1 ERBB2
153 lymphangioleiomyomatosis 10.9 VEGFA PGR IGF1 ESR1
154 uterine corpus serous adenocarcinoma 10.9 TP53 ERBB2 BRCA1
155 leiomyosarcoma 10.9 VEGFA TP53 PGR ESR1
156 retinal vascular disease 10.9 VEGFA MIR199A1 IGF1 CASP3
157 squamous cell carcinoma, head and neck 10.9 VEGFA TP53 MIR199A1 ERBB2 EGF CYP1A1
158 juvenile nasopharyngeal angiofibroma 10.9 VEGFA PGR ESR1
159 thoracic benign neoplasm 10.9 TP53 PRLR PGR KRT5 ESR1 ERBB2
160 breast benign neoplasm 10.9 TP53 PRLR PGR KRT5 ESR1 ERBB2
161 apocrine sweat gland neoplasm 10.9 PGR KRT5 ERBB2
162 breast cystic hypersecretory carcinoma 10.9 KRT5 ERBB2
163 endometriosis of ovary 10.9 PGR ESR2 ESR1
164 salivary gland carcinoma 10.9 TP53 ESR2 ERBB2 BRCA1
165 functioning pituitary adenoma 10.9 PRLR MIR199A1 IGF1
166 macular degeneration, age-related, 1 10.8 VEGFA IGF1 EGF CTSD CASP3
167 estrogen-receptor negative breast cancer 10.8 VEGFA PGR IGF1 ESR1 ERBB2 EGF
168 germ cell cancer 10.8 MIR199A1 ESR2 ESR1 CYP1B1
169 cell type benign neoplasm 10.8 VEGFA TP53 PGR MIR199A1 IGF1 ESR1
170 estrogen-receptor positive breast cancer 10.8 VEGFA TP53 PGR ESR2 ESR1 ERBB2
171 hypertension, essential 10.8 VEGFA TP53 IGF1 ESR1 EGF COMT
172 tonsil cancer 10.8 TP53 PGR MIR199A1 KRT5 ESR1 ERBB2
173 autosomal genetic disease 10.8 VEGFA TP53 MIR199A1 IGF1 ESR2 ESR1
174 endocervical adenocarcinoma 10.8 TP53 PGR ESR1
175 bone marrow cancer 10.8 VEGFA TP53 MIR199A1 CASP3
176 thyroid gland cancer 10.8 VEGFA TP53 MIR199A1 ESR1 ERBB2 EGF
177 cystadenocarcinoma 10.8 VEGFA TP53 PGR MIR199A1 ESR2 ERBB2
178 luminal breast carcinoma 10.8 TP53 PGR KRT5 ESR1 ERBB2 EGF
179 uterine corpus cancer 10.8 TP53 PGR ESR1 ERBB2 BRCA1
180 oral cancer 10.8 TP53 CYP1A1 CASP3
181 endometrial stromal sarcoma 10.8 TP53 PGR ESR2 ESR1
182 bartholin's gland adenoid cystic carcinoma 10.8 PGR ESR1
183 chronic tympanitis 10.8 PGR ESR1
184 fallopian tube disease 10.8 VEGFA TP53 BRCA1
185 breast juvenile papillomatosis 10.8 PGR ESR1 ERBB2 BRCA1
186 pre-malignant neoplasm 10.8 VEGFA TP53 PGR KRT5 ESR1 ERBB2
187 ovary adenocarcinoma 10.8 VEGFA TP53 PGR ESR1 ERBB2 EGF
188 gastric ulcer 10.8 VEGFA TFF1 EGF
189 primary peritoneal carcinoma 10.8 VEGFA TP53 PGR ERBB2 BRCA1
190 ovarian clear cell adenocarcinoma 10.8 TP53 PGR ESR2
191 autosomal dominant polycystic kidney disease 10.8 VEGFA IGF1 EGF CASP3
192 endosalpingiosis 10.8 TP53 PGR ESR1 BRCA1
193 pediatric angiosarcoma 10.8 VEGFA TP53
194 intracystic papillary adenoma 10.8 PGR KRT5 ESR1 ERBB2 BRCA1
195 kidney cancer 10.8 VEGFA TP53 MIR199A1 EGF COMT
196 ovarian serous cystadenocarcinoma 10.8 VEGFA TP53 PGR ESR2 ERBB2 BRCA1
197 muscular disease 10.8 VEGFA TP53 PGR MIR199A1 IGF1 ESR1
198 granulomatous endometritis 10.8 PGR ESR1
199 large cell neuroendocrine carcinoma 10.8 PGR ESR1 ERBB2
200 renal cell carcinoma, papillary, 1 10.8 VEGFA TP53 MIR199A1 ERBB2
201 osteonecrosis 10.8 VEGFA IGF1 ESR1
202 connective tissue cancer 10.8 VEGFA TP53 MIR199A1 CASP3
203 central nervous system cancer 10.8 VEGFA TP53 MIR199A1 EGF
204 lung cancer susceptibility 3 10.8 VEGFA TP53 MIR199A1 KRT5 ESR2 ESR1
205 vulva basal cell carcinoma 10.8 KRT5 ERBB2
206 ovarian cystadenocarcinoma 10.8 TP53 ERBB2 BRCA1
207 leukocyte disease 10.8 VEGFA TP53 MIR199A1 CASP3
208 calcifying aponeurotic fibroma 10.8 PGR EGF
209 colonic disease 10.8 TP53 MIR199A1 ESR1 CTSD
210 mouth disease 10.8 TP53 MIR199A1 ESR2 ESR1
211 pleural disease 10.8 VEGFA TP53 KRT5
212 adenoid cystic carcinoma 10.8 VEGFA TP53 PGR KRT5 ERBB2 EGF
213 breast squamous cell carcinoma 10.8 TP53 ERBB2
214 pituitary gland disease 10.8 PRLR IGFBP3 IGF1
215 papillary adenocarcinoma 10.8 TP53 PGR ERBB2 BRCA1
216 scirrhous adenocarcinoma 10.8 PGR ERBB2
217 ovarian serous carcinoma 10.8 TP53 MIR199A1 ERBB2
218 esophageal basaloid squamous cell carcinoma 10.8 TP53 KRT5
219 pancreas disease 10.8 VEGFA TP53 MIR199A1 IGF1
220 leukemia, acute myeloid 10.8 VEGFA TP53 MIR199A1 ESR1 ERBB2 EGF
221 childhood leukemia 10.8 TP53 IGF1 CYP1A1
222 mixed epithelial stromal tumour 10.8 CYP1B1 COMT
223 colon adenoma 10.8 VEGFA EGF CASP3
224 lung leiomyoma 10.8 PGR ESR1
225 vulvar syringoma 10.8 PGR ESR1
226 trigonitis 10.8 PGR ESR1
227 endometrial cancer 10.8 VEGFA TP53 PGR MIR199A1 IGFBP3 IGF1
228 primary pigmented nodular adrenocortical disease 10.8 PGR ESR2 ESR1
229 prostate cancer 10.8 VEGFA TP53 PRLR PGR MIR199A1 KRT5
230 spindle cell carcinoma 10.8 PGR KRT5 ESR1
231 female reproductive endometrioid cancer 10.8 TP53 PGR MIR199A1 ESR1 ERBB2 BRCA1
232 microvascular complications of diabetes 1 10.8 VEGFA IGFBP3 IGF1
233 papillary serous adenocarcinoma 10.8 TP53 PGR BRCA1
234 glycogen-rich clear cell breast carcinoma 10.8 PRLR PGR
235 ovarian cancer 10.8 VEGFA TP53 TFF1 PGR MIR199A1 IGFBP3
236 esophagitis 10.8 VEGFA TP53 EGF
237 lung cancer 10.8 VEGFA TP53 PGR MIR199A1 IGFBP3 IGF1
238 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.8 IGFBP3 IGF1
239 carpal tunnel syndrome 10.8 VEGFA PGR ESR1
240 ovary epithelial cancer 10.8 VEGFA TP53 PGR MIR199A1 ESR1 ERBB2
241 malignant ovarian surface epithelial-stromal neoplasm 10.8 VEGFA TP53 PGR MIR199A1 ESR1 ERBB2
242 serous cystadenocarcinoma 10.8 VEGFA TP53 PGR MIR199A1 ESR2 ERBB2
243 vagina leiomyosarcoma 10.8 PGR ESR1
244 familial ovarian cancer 10.8 ESR1 BRCA1
245 colorectal cancer 10.8 VEGFA TP53 MIR199A1 IGFBP3 IGF1 ESR2
246 adult hepatocellular carcinoma 10.8 TP53 EGF
247 contractures, pterygia, and variable skeletal fusions syndrome 1a 10.8 VEGFA TP53 MIR199A1 BRCA1
248 nasopharyngeal carcinoma 10.8 VEGFA TP53 ERBB2 EGF CASP3
249 pancreatic ductal adenocarcinoma 10.8 VEGFA TP53 MIR199A1 ERBB2
250 bladder cancer 10.8 VEGFA TP53 ERBB2 EGF CYP1A1 CASP3
251 thoracic cancer 10.8 TP53 PGR MIR199A1 ESR1 ERBB2 BRCA1
252 adult type testicular granulosa cell tumor 10.8 PGR ESR1
253 uterine anomalies 10.8 TP53 PGR MIR199A1 ESR1
254 synchronous bilateral breast carcinoma 10.8 PGR BRCA1
255 gallbladder cancer 10.8 VEGFA TP53 ERBB2 EGF
256 breast leiomyoma 10.8 PGR ESR1
257 mucositis 10.8 VEGFA EGF CASP3
258 melanoma, uveal 10.8 VEGFA TP53 MIR199A1 BRCA1
259 diabetes mellitus, noninsulin-dependent 10.8 VEGFA TP53 MIR199A1 IGFBP3 IGF1 ESR2
260 external ear carcinoma 10.7 PGR KRT5
261 hepatocellular carcinoma 10.7 VEGFA TP53 RHOC MIR199A1 IGF1 ESR1
262 necrotizing sialometaplasia 10.7 TP53 KRT5
263 osteogenic sarcoma 10.7 TP53 IGF1 EGF CASP3
264 gonadal disease 10.7 TP53 MIR199A1 IGF1 BRCA1
265 rare breast tumor 10.7 TP53 ESR1 ERBB2 BRCA1
266 intestinal benign neoplasm 10.7 VEGFA TP53 MIR199A1
267 bone resorption disease 10.7 MIR199A1 IGF1 ESR1
268 cerebral hypoxia 10.7 IGF1 CASP3
269 parotid gland cancer 10.7 TP53 ERBB2
270 intravenous leiomyomatosis 10.7 PGR ESR1
271 eccrine papillary adenocarcinoma 10.7 PGR KRT5
272 bone remodeling disease 10.7 MIR199A1 IGF1 ESR1
273 liver leiomyoma 10.7 PGR ESR1
274 brain cancer 10.6 VEGFA TP53 EGF CYP1A1 CASP3
275 breast adenoid cystic carcinoma 10.6 PGR ERBB2
276 endocrine organ benign neoplasm 10.6 TP53 MIR199A1 IGF1
277 bladder urothelial carcinoma 10.6 VEGFA TP53 ERBB2 CASP3
278 pituitary adenoma, prolactin-secreting 10.6 IGF1 ESR2 ESR1
279 lynch syndrome 10.6 TP53 IGF1 CYP1A1 BRCA1
280 pancreatic cancer 10.6 VEGFA TP53 TFF1 MIR199A1 ERBB2 EGF
281 craniopharyngioma 10.6 VEGFA KRT5 IGF1
282 wolffian duct adenocarcinoma 10.6 TP53 ESR1
283 vulvar leiomyoma 10.4 PGR ESR1
284 eccrine sweat gland cancer 10.4 TP53 KRT5
285 pleomorphic adenoma carcinoma 10.3 TP53 ERBB2
286 squamous cell papilloma 10.2
287 breast cyst 10.1
288 lipomatosis, multiple 9.9
289 pleomorphic lipoma 9.9
290 adenoma 9.9
291 lactocele 9.9
292 benign breast phyllodes tumor 9.9
293 granulomatous mastitis 9.9
294 goiter 9.9
295 hyperprolactinemia 9.8
296 hypothyroidism 9.8
297 fibromatosis 9.8
298 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.8
299 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.8
300 bent bone dysplasia syndrome 9.8
301 polycystic ovary syndrome 9.8
302 adenocarcinoma 9.8
303 anovulation 9.8
304 myopathy 9.8
305 premenstrual tension 9.8
306 48,xyyy 9.8
307 chromosomal triplication 9.8
308 epidermoid cysts 9.7
309 cowden syndrome 1 9.7
310 sarcoidosis 1 9.7
311 lymphoma, hodgkin, classic 9.7
312 lymphoma, non-hodgkin, familial 9.7
313 body mass index quantitative trait locus 1 9.7
314 anxiety 9.7
315 ptosis 9.7
316 hyperandrogenism 9.7
317 dermatitis 9.7
318 proliferative type fibrocystic change of breast 9.7
319 thyroid gland disease 9.7
320 cowden syndrome 9.7
321 vasculitis 9.7
322 benign mammary dysplasia 9.7
323 neurofibromatosis, type ii 9.5
324 autoimmune disease 9.5
325 hair whorl 9.5
326 otitis media 9.5
327 scleroderma, familial progressive 9.5
328 triiodothyronine receptor auxiliary protein 9.5
329 amelogenesis imperfecta, hypomaturation type, iia1 9.5
330 diabetes mellitus, insulin-dependent 9.5
331 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.5
332 proteasome-associated autoinflammatory syndrome 1 9.5
333 arts syndrome 9.5
334 prostatic hyperplasia, benign 9.5
335 body mass index quantitative trait locus 9 9.5
336 body mass index quantitative trait locus 8 9.5
337 breast-ovarian cancer, familial 1 9.5
338 meningioma, radiation-induced 9.5
339 body mass index quantitative trait locus 4 9.5
340 body mass index quantitative trait locus 10 9.5
341 hypercholanemia, familial 9.5
342 body mass index quantitative trait locus 7 9.5
343 li-fraumeni syndrome 2 9.5
344 human immunodeficiency virus type 1 9.5
345 body mass index quantitative trait locus 12 9.5
346 sarcoidosis 2 9.5
347 body mass index quantitative trait locus 14 9.5
348 body mass index quantitative trait locus 18 9.5
349 sting-associated vasculopathy, infantile-onset 9.5
350 body mass index quantitative trait locus 19 9.5
351 body mass index quantitative trait locus 20 9.5
352 fibroma 9.5
353 sexual disorder 9.5
354 alexithymia 9.5
355 sting-associated vasculopathy with onset in infancy 9.5
356 spinal meningioma 9.5
357 graves' disease 9.5
358 leukemia 9.5
359 nodular goiter 9.5
360 eclampsia 9.5
361 facial paralysis 9.5
362 lymphangioma 9.5
363 cholera 9.5
364 neuroendocrine carcinoma 9.5
365 melanoma 9.5
366 trichomoniasis 9.5
367 hyperinsulinism 9.5
368 cervicitis 9.5
369 prostatic adenoma 9.5
370 interstitial lung disease 9.5
371 papillary carcinoma 9.5
372 neurilemmoma 9.5
373 liposarcoma 9.5
374 histiocytosis 9.5
375 cellulitis 9.5
376 angiolipoma 9.5
377 thrombophlebitis 9.5
378 hidradenoma 9.5
379 secondary syphilis 9.5
380 syphilis 9.5
381 myofibroma 9.5
382 secretory meningioma 9.5
383 lymphoplasmacyte-rich meningioma 9.5
384 infertility 9.5
385 hereditary breast ovarian cancer syndrome 9.5
386 thyroiditis 9.5
387 pseudosarcomatous fibromatosis 9.5
388 lung disease 9.5
389 bullous pemphigoid 9.5
390 herpes zoster 9.5
391 fasciitis 9.5
392 alopecia 9.5
393 keloid disorder 9.5
394 47,xyy 9.5
395 cytokine deficiency 9.5
396 germ cells tumors 9.5
397 gigantomastia 9.5
398 granulomatous lobular mastitis 9.5
399 pyogenic granuloma 9.5
400 depression 9.5
401 back pain 9.5
402 supernumerary breasts 9.5
403 rare malignant breast tumor 9.5
404 systemic autoimmune disease 9.5
405 rare lymphatic malformation 9.5
406 chronic enteropathy associated with slco2a1 gene 9.5
407 rare tumor 9.5
408 polyploidy 9.5
409 overgrowth syndrome 9.5
410 thyroid carcinoma 9.5
411 thyroid tumor 9.5

Graphical network of the top 20 diseases related to Breast Disease:



Diseases related to Breast Disease

Symptoms & Phenotypes for Breast Disease

UMLS symptoms related to Breast Disease:


pruritus, exanthema, pelvic pain, mastodynia, breast engorgement, nipple discharge, signs and symptoms in breast, other signs and symptoms in breast, breast pain female

GenomeRNAi Phenotypes related to Breast Disease according to GeneCards Suite gene sharing:

26 (showing 2, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 CASP3 ERBB2 IGF1
2 Decreased viability with paclitaxel GR00179-A-2 8.92 IGF1

MGI Mouse Phenotypes related to Breast Disease:

45 (showing 21, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.43 BRCA1 CASP3 COMT CTSD CYP1A1 EGF
2 homeostasis/metabolism MP:0005376 10.43 BRCA1 CASP3 COMT CTSD CYP1A1 CYP1B1
3 growth/size/body region MP:0005378 10.42 BRCA1 CASP3 CTSD CYP1A1 EGF ERBB2
4 behavior/neurological MP:0005386 10.4 BRCA1 CASP3 COMT CTSD ERBB2 ESR1
5 cellular MP:0005384 10.35 BRCA1 CASP3 CTSD ERBB2 ESR1 ESR2
6 integument MP:0010771 10.34 BRCA1 CASP3 CTSD EGF ERBB2 ESR1
7 cardiovascular system MP:0005385 10.32 BRCA1 CASP3 COMT CYP1A1 ERBB2 ESR1
8 immune system MP:0005387 10.32 BRCA1 CASP3 COMT CTSD CYP1A1 EGF
9 digestive/alimentary MP:0005381 10.31 BRCA1 CASP3 CTSD EGF ERBB2 ESR1
10 hematopoietic system MP:0005397 10.31 BRCA1 CASP3 COMT CTSD CYP1A1 ESR1
11 limbs/digits/tail MP:0005371 10.22 BRCA1 ERBB2 ESR1 ESR2 IGF1 IGFBP3
12 neoplasm MP:0002006 10.21 BRCA1 CYP1B1 ERBB2 ESR1 ESR2 IGF1
13 muscle MP:0005369 10.16 BRCA1 CASP3 ERBB2 ESR1 ESR2 IGF1
14 adipose tissue MP:0005375 10.14 BRCA1 ESR1 ESR2 IGF1 IGFBP3 PRLR
15 nervous system MP:0003631 10.14 BRCA1 CASP3 COMT CTSD ERBB2 ESR1
16 normal MP:0002873 10.02 BRCA1 CYP1A1 EGF ERBB2 ESR1 ESR2
17 no phenotypic analysis MP:0003012 9.97 CASP3 CYP1A1 ESR1 ESR2 KRT5 PGR
18 reproductive system MP:0005389 9.93 BRCA1 CASP3 COMT EGF ERBB2 ESR1
19 renal/urinary system MP:0005367 9.86 BRCA1 CASP3 COMT ESR1 ESR2 IGF1
20 respiratory system MP:0005388 9.61 BRCA1 CASP3 COMT ERBB2 ESR1 ESR2
21 skeleton MP:0005390 9.36 BRCA1 CASP3 ERBB2 ESR1 ESR2 IGF1

Drugs & Therapeutics for Breast Disease

Drugs for Breast Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 200, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
2
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
3
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
4
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
5 Retinol palmitate Phase 4
6 retinol Phase 4
7 Hypolipidemic Agents Phase 4
8 Evening Primrose Phase 4
9 Analgesics, Non-Narcotic Phase 4
10 Analgesics Phase 4
11 Anti-Inflammatory Agents, Non-Steroidal Phase 4
12 Lipid Regulating Agents Phase 4
13 Anesthetics, General Phase 4
14 Central Nervous System Depressants Phase 4
15 Anesthetics, Local Phase 4
16 Anti-Inflammatory Agents Phase 4
17 Dermatologic Agents Phase 4
18 glucocorticoids Phase 4
19 Hydrocortisone hemisuccinate Phase 4
20 Respiratory System Agents Phase 4
21 Anti-Asthmatic Agents Phase 4
22 Betamethasone Valerate Phase 4 2152-44-5
23 Hydrocortisone-17-butyrate Phase 4
24 Hydrocortisone 17-butyrate 21-propionate Phase 4
25 Betamethasone-17,21-dipropionate Phase 4
26 Betamethasone sodium phosphate Phase 4
27 Betamethasone benzoate Phase 4
28 Chelating Agents Phase 4
29 Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate Phase 4
30
Evening primrose oil Investigational, Nutraceutical Phase 4 308064-97-3
31
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
32
Remifentanil Approved Phase 3 132875-61-7 60815
33
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
34
tannic acid Approved Phase 3 1401-55-4
35
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
36
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
37
Ibuprofen Approved Phase 3 15687-27-1 3672
38
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
39
Acetaminophen Approved Phase 3 103-90-2 1983
40
Codeine Approved, Illicit Phase 3 76-57-3 5284371
41
Mesna Approved, Investigational Phase 3 3375-50-6 598
42
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
43
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
44
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
45
Fulvestrant Approved, Investigational Phase 3 129453-61-8 104741 17756771
46
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
47
Bevacizumab Approved, Investigational Phase 3 216974-75-3
48
Lenograstim Approved, Investigational Phase 3 135968-09-1
49
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
50
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
51
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
52
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 6055-19-2, 50-18-0 2907
53
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
54
Epirubicin Approved Phase 2, Phase 3 56420-45-2 41867
55
Goserelin Approved Phase 2, Phase 3 65807-02-5, 1233494-97-7 47725 5311128
56
Phenobarbital Approved, Investigational Phase 2, Phase 3 50-06-6 4763
57 Protective Agents Phase 3
58 Narcotics Phase 3
59 Analgesics, Opioid Phase 3
60 Neuromuscular Agents Phase 3
61 Cholinergic Agents Phase 3
62 Antipyretics Phase 3
63 Cyclooxygenase Inhibitors Phase 3
64 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
65 Antitussive Agents Phase 3
66 2,2'-dithiodiethanesulfonic acid Phase 3
67 Pharmaceutical Solutions Phase 3
68 abobotulinumtoxinA Phase 3
69 Acetylcholine Release Inhibitors Phase 3
70 Botulinum Toxins Phase 3
71 Botulinum Toxins, Type A Phase 3
72 Cyclooxygenase 2 Inhibitors Phase 3
73 Antibodies Phase 3
74 Immunoglobulins Phase 3
75 Antibodies, Monoclonal Phase 3
76 Antineoplastic Agents, Immunological Phase 3
77 Triamcinolone diacetate Phase 3
78 triamcinolone acetonide Phase 3
79 Triamcinolone hexacetonide Phase 3
80 Angiogenesis Inhibitors Phase 3
81 Estrogens Phase 2, Phase 3
82 Estrogen Antagonists Phase 2, Phase 3
83 Estrogen Receptor Antagonists Phase 2, Phase 3
84 Hormone Antagonists Phase 2, Phase 3
85 Hormones Phase 2, Phase 3
86 Selective Estrogen Receptor Modulators Phase 2, Phase 3
87 Antineoplastic Agents, Hormonal Phase 2, Phase 3
88 Antirheumatic Agents Phase 2, Phase 3
89 Estrogen Receptor Modulators Phase 2, Phase 3
90 Immunologic Factors Phase 2, Phase 3
91 Hypnotics and Sedatives Phase 2, Phase 3
92 Immunosuppressive Agents Phase 2, Phase 3
93 Antimitotic Agents Phase 2, Phase 3
94 Steroid Synthesis Inhibitors Phase 2, Phase 3
95 Aromatase Inhibitors Phase 2, Phase 3
96 Neurotransmitter Agents Phase 2, Phase 3
97 Antibiotics, Antitubercular Phase 2, Phase 3
98 Anti-Bacterial Agents Phase 2, Phase 3
99 Alkylating Agents Phase 2, Phase 3
100
Liposomal doxorubicin Phase 2, Phase 3 31703
101 Topoisomerase Inhibitors Phase 2, Phase 3
102 Excitatory Amino Acid Antagonists Phase 2, Phase 3
103 Anticonvulsants Phase 2, Phase 3
104 GABA Modulators Phase 2, Phase 3
105 GABA Agents Phase 2, Phase 3
106 Excitatory Amino Acids Phase 2, Phase 3
107 Cytochrome P-450 CYP3A Inducers Phase 2, Phase 3
108
Danazol Approved Phase 2 17230-88-5 28417
109
Iodine Approved, Investigational Phase 2 7553-56-2 807
110
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
111
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
112
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
113
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
114
Zoledronic Acid Approved Phase 2 118072-93-8 68740
115
Simvastatin Approved Phase 2 79902-63-9 54454
116
Leflunomide Approved, Investigational Phase 1, Phase 2 75706-12-6 3899
117
Pertuzumab Approved Phase 1, Phase 2 145040-37-5, 380610-27-5 2540
118
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
119
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
120
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
121
Exemestane Approved, Investigational Phase 2 107868-30-4 60198